LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · Insiders net selling
Net selling: insiders sold $1.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $16K to $65K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 3, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.25 expected
Estimates as of Nov 9, 2026
EPS expected
-$0.55 to $0.45
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 3, 2026 | $0.57est. $0.25 | +130.87%beat | $480.1MSEC filing | +21.8%from $394.2M |
| Jun 30, 2026Reported Jul 28, 2026 | $0.70est. $0.29 | +141.33%beat | $496.0MSEC filing | +27.0%from $390.7M |
| Mar 31, 2026Reported May 5, 2026 | $0.38est. -$0.04 | +$0.42beat | $392.9MSEC filing | +28.2%from $306.5M |
| Dec 31, 2025Reported Feb 25, 2026 | $0.48est. $0.45 | +7.74%beat | $384.5MAlpha Vantage | -10.6%from $430.0M |
| Sep 30, 2025Reported Oct 28, 2025 | $0.65est. $0.39 | +66.67%beat | $394.2MSEC filing | +4.2%from $378.1M |
| Jun 30, 2025Reported Jul 29, 2025 | $0.68est. $0.40 | +70.00%beat | $390.7MSEC filing | -2.1%from $399.1M |
| Mar 31, 2025Reported May 1, 2025 | $0.29est. $0.24 | +20.83%beat | $306.5MSEC filing | -12.5%from $350.4M |
| Dec 31, 2024Reported Feb 12, 2025 | $1.05est. $0.76 | +38.16%beat | $430.0MAlpha Vantage | +13.9%from $377.5M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $384.5M | $392.9M | $496.0M | $480.1M |
| Cost of what it sold | $46.2M | $61.6M | $98.1M | $94.2M |
| Gross profit | $338.3M | $331.3M | $397.9M | $385.9M |
| What it spent | ||||
| Research and development | $93.0M | $103.3M | $112.9M | $121.1M |
| Sales and admin | $100.8M | $109.0M | $63.3M | $208.5M |
| Other operating costs | $86.4M | $167.2M | $203.3M | $20.3M |
| Total operating expenses | $280.2M | $379.6M | $379.5M | $349.9M |
| What was left | ||||
| Operating profit | $58.1M | -$48.3M | $18.4M | $36.0M |
| Interest on debt | $12.3M | $20.9M | $25.9M | $27.6M |
| Profit before tax | $60.4M | -$61.9M | -$1.9M | $14.7M |
| Tax | $11.0M | $4.6M | -$2.4M | -$1.6M |
| Net profit | $49.3M | -$66.5M | $501.0K | $16.3M |
| EBITDA | $76.5M | -$21.6M | $54.3M | $69.4M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Form 4 Alkermes plc.: David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) For: 3 November
NeutralNov 4Alkermes plc (ALKS)
Leans bullishNov 3Alkermes begins phase 2 trial of depression treatment candidate
Leans bullishOct 3134 macro signals shaping ALKS right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
